SE9902386D0 - New formulation - Google Patents

New formulation

Info

Publication number
SE9902386D0
SE9902386D0 SE9902386A SE9902386A SE9902386D0 SE 9902386 D0 SE9902386 D0 SE 9902386D0 SE 9902386 A SE9902386 A SE 9902386A SE 9902386 A SE9902386 A SE 9902386A SE 9902386 D0 SE9902386 D0 SE 9902386D0
Authority
SE
Sweden
Prior art keywords
omeprazole
dosage form
core material
new formulation
alkaline
Prior art date
Application number
SE9902386A
Other languages
English (en)
Inventor
Per Johan Lundberg
Brita Sjoeblom
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9902386A priority Critical patent/SE9902386D0/sv
Publication of SE9902386D0 publication Critical patent/SE9902386D0/sv
Priority to AT00946614T priority patent/ATE291901T1/de
Priority to DE60019116T priority patent/DE60019116T2/de
Priority to EP00946614A priority patent/EP1191926B1/en
Priority to SI200030673T priority patent/SI1191926T1/xx
Priority to PCT/SE2000/001310 priority patent/WO2000078293A1/en
Priority to NZ516186A priority patent/NZ516186A/en
Priority to BR0011894-0A priority patent/BR0011894A/pt
Priority to AU60344/00A priority patent/AU778158B2/en
Priority to SK1825-2001A priority patent/SK285326B6/sk
Priority to TR2001/03693T priority patent/TR200103693T2/xx
Priority to HU0201489A priority patent/HUP0201489A3/hu
Priority to DK00946614T priority patent/DK1191926T3/da
Priority to IL14681800A priority patent/IL146818A0/xx
Priority to MXPA01012636A priority patent/MXPA01012636A/es
Priority to CA002376226A priority patent/CA2376226C/en
Priority to KR1020017016442A priority patent/KR100717661B1/ko
Priority to CNB008093369A priority patent/CN1243547C/zh
Priority to ES00946614T priority patent/ES2235912T3/es
Priority to PT00946614T priority patent/PT1191926E/pt
Priority to PL00352873A priority patent/PL352873A1/xx
Priority to JP2001504358A priority patent/JP2003502359A/ja
Priority to EEP200100693A priority patent/EE200100693A/xx
Priority to RU2001132861/15A priority patent/RU2240110C2/ru
Priority to UA2001128420A priority patent/UA73302C2/uk
Priority to CZ20014579A priority patent/CZ20014579A3/cs
Priority to ZA200109803A priority patent/ZA200109803B/en
Priority to IL146818A priority patent/IL146818A/en
Priority to NO20016346A priority patent/NO20016346L/no
Priority to IS6209A priority patent/IS6209A/is
Priority to HK02106171.6A priority patent/HK1044480B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
SE9902386A 1999-06-22 1999-06-22 New formulation SE9902386D0 (sv)

Priority Applications (31)

Application Number Priority Date Filing Date Title
SE9902386A SE9902386D0 (sv) 1999-06-22 1999-06-22 New formulation
CA002376226A CA2376226C (en) 1999-06-22 2000-06-20 New formulation
MXPA01012636A MXPA01012636A (es) 1999-06-22 2000-06-20 Formas de dosis farmaceuticas orales nuevas..
KR1020017016442A KR100717661B1 (ko) 1999-06-22 2000-06-20 신규 제형
DE60019116T DE60019116T2 (de) 1999-06-22 2000-06-20 Neue omeprazole und (s)-omeprazole zusammensetzung
SI200030673T SI1191926T1 (sv) 1999-06-22 2000-06-20
PCT/SE2000/001310 WO2000078293A1 (en) 1999-06-22 2000-06-20 New formulation
NZ516186A NZ516186A (en) 1999-06-22 2000-06-20 Oral dosage form of proton pump inhibitor
BR0011894-0A BR0011894A (pt) 1999-06-22 2000-06-20 Forma de dosagem oral, processo para a fabricação de forma de dosagem, uso de forma de dosagem farmacêutica oral, e, métodos para aumentar inibição de secreção do ácido gástrico e para aumentar o efeito terapêutico no tratamento de distúrbios gastrointestinais associados com excesso de secreção ácida
AU60344/00A AU778158B2 (en) 1999-06-22 2000-06-20 New formulation
SK1825-2001A SK285326B6 (sk) 1999-06-22 2000-06-20 Orálna dávková forma obsahujúca omeprazol a S-omeprazol, spôsob jej prípravy a jej použitie
TR2001/03693T TR200103693T2 (tr) 1999-06-22 2000-06-20 Yeni formülasyon
HU0201489A HUP0201489A3 (en) 1999-06-22 2000-06-20 New formulation
DK00946614T DK1191926T3 (da) 1999-06-22 2000-06-20 Ny omeprazol- og (S)-omeprazolformulering
IL14681800A IL146818A0 (en) 1999-06-22 2000-06-20 New formulation
AT00946614T ATE291901T1 (de) 1999-06-22 2000-06-20 Neue omeprazole und (s)-omeprazole zusammensetzung
CZ20014579A CZ20014579A3 (cs) 1999-06-22 2000-06-20 Nový přípravek
EP00946614A EP1191926B1 (en) 1999-06-22 2000-06-20 New omeprazole and (s)-omeprazole formulation
CNB008093369A CN1243547C (zh) 1999-06-22 2000-06-20 新的制剂
ES00946614T ES2235912T3 (es) 1999-06-22 2000-06-20 Nueva formulacion de omeprazol y (s)-omeprazol.
PT00946614T PT1191926E (pt) 1999-06-22 2000-06-20 Novas formulacoes de omeprazole e (s)- omeprazole
PL00352873A PL352873A1 (en) 1999-06-22 2000-06-20 New formulation
JP2001504358A JP2003502359A (ja) 1999-06-22 2000-06-20 新規製剤
EEP200100693A EE200100693A (et) 1999-06-22 2000-06-20 Uus ravimvorm
RU2001132861/15A RU2240110C2 (ru) 1999-06-22 2000-06-20 Новый препарат
UA2001128420A UA73302C2 (en) 1999-06-22 2000-06-20 Oral dosage form of omeprazole without enteric coating
ZA200109803A ZA200109803B (en) 1999-06-22 2001-11-28 New formulation.
IL146818A IL146818A (en) 1999-06-22 2001-11-29 Medicinal product containing as active substance omeprazole, S-omeprazole or its alkaline salts
NO20016346A NO20016346L (no) 1999-06-22 2001-12-21 Ny formulering
IS6209A IS6209A (is) 1999-06-22 2001-12-21 Ný blanda
HK02106171.6A HK1044480B (zh) 1999-06-22 2002-08-22 奧美拉唑和(s)-奧美拉唑的新製劑

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9902386A SE9902386D0 (sv) 1999-06-22 1999-06-22 New formulation

Publications (1)

Publication Number Publication Date
SE9902386D0 true SE9902386D0 (sv) 1999-06-22

Family

ID=20416209

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9902386A SE9902386D0 (sv) 1999-06-22 1999-06-22 New formulation

Country Status (29)

Country Link
EP (1) EP1191926B1 (sv)
JP (1) JP2003502359A (sv)
KR (1) KR100717661B1 (sv)
CN (1) CN1243547C (sv)
AT (1) ATE291901T1 (sv)
AU (1) AU778158B2 (sv)
BR (1) BR0011894A (sv)
CA (1) CA2376226C (sv)
CZ (1) CZ20014579A3 (sv)
DE (1) DE60019116T2 (sv)
DK (1) DK1191926T3 (sv)
EE (1) EE200100693A (sv)
ES (1) ES2235912T3 (sv)
HK (1) HK1044480B (sv)
HU (1) HUP0201489A3 (sv)
IL (2) IL146818A0 (sv)
IS (1) IS6209A (sv)
MX (1) MXPA01012636A (sv)
NO (1) NO20016346L (sv)
NZ (1) NZ516186A (sv)
PL (1) PL352873A1 (sv)
PT (1) PT1191926E (sv)
RU (1) RU2240110C2 (sv)
SE (1) SE9902386D0 (sv)
SK (1) SK285326B6 (sv)
TR (1) TR200103693T2 (sv)
UA (1) UA73302C2 (sv)
WO (1) WO2000078293A1 (sv)
ZA (1) ZA200109803B (sv)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
CN100553625C (zh) 2002-04-09 2009-10-28 弗拉梅技术公司 活性成分微囊的口服混悬液
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
CA2517289A1 (en) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Stable pharmaceutical composition of rabeprazole and processes for their preparation
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1696889A1 (en) * 2003-08-28 2006-09-06 Ranbaxy Laboratories, Ltd. Pharmaceutical compositions of benzimidazole and processes for their preparation
EP1660052A2 (en) * 2003-09-03 2006-05-31 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
US8165651B2 (en) 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2008510804A (ja) * 2004-08-23 2008-04-10 オークランド ユニサービシズ リミテッド 胃の治療法およびそのための組成物
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
FR2885526B1 (fr) * 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
CN101534808A (zh) 2005-06-27 2009-09-16 拜维尔实验室国际有限公司 丁氨苯丙酮盐的改良释放配制品
BRPI0620787A2 (pt) * 2005-12-28 2011-11-22 Takeda Pharmaceutical preparação sólida
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
AU2007278986B2 (en) 2006-07-25 2010-09-16 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
EP2079448A2 (en) * 2006-10-10 2009-07-22 Dexcel Pharma Technologies Ltd. Improved release of statins in the intestine
JP2012502015A (ja) 2008-09-09 2012-01-26 アストラゼネカ・アクチエボラーグ 必要がある患者に医薬組成物を送達するための方法
EA201290026A1 (ru) 2009-06-25 2012-07-30 Астразенека Аб Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
EA034288B1 (ru) 2011-05-13 2020-01-24 Эб Ип Хибритабс Б.В. Система доставки лекарственного средства
EP2586429A1 (en) * 2011-10-26 2013-05-01 Freund Pharmatec Ltd. Multi-unit drug delivery device for pulsatile or sustained release
WO2013101897A2 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2013122554A1 (en) 2012-02-14 2013-08-22 Mahmut Bilgic Pellet formulations comprising esomeprazole
CN103127026B (zh) * 2013-02-05 2017-02-15 悦康药业集团有限公司 一种奥美拉唑肠溶胶囊及其制备方法
RU2683203C2 (ru) 2013-12-31 2019-03-26 Эбботт Дайабитиз Кэр Инк. Снабженный автономным питанием датчик аналита и использующие его устройства
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
RU2614730C1 (ru) * 2016-02-05 2017-03-28 Игорь Юрьевич Чичерин Антибактериальное средство и способ лечения кишечного иерсиниоза, или псевдотуберкулеза, или эшерихиоза
US10736855B2 (en) * 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
JP6462625B2 (ja) * 2016-04-06 2019-01-30 ニプロ株式会社 カルシウムブロッカーを含有する錠剤
JP6426115B2 (ja) * 2016-04-06 2018-11-21 ニプロ株式会社 カルシウムブロッカーを含有する固形医薬組成物
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN109125282B (zh) * 2018-09-05 2020-07-14 珠海润都制药股份有限公司 一种奥美拉唑肠溶胶囊及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
ZA979937B (en) * 1996-11-06 1999-05-18 Sharmatek Inc Delayed delivery system for acid-sensitive drugs
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
ATE303809T1 (de) * 1997-12-08 2005-09-15 Altana Pharma Ag Orale verabreichungsform enthaltend einen protonenpumpeninhbitor (z.b. pantoprazole)
CA2340054C (en) * 1998-08-12 2005-10-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles

Also Published As

Publication number Publication date
ATE291901T1 (de) 2005-04-15
SK285326B6 (sk) 2006-11-03
NZ516186A (en) 2003-11-28
EE200100693A (et) 2003-02-17
KR100717661B1 (ko) 2007-05-14
NO20016346L (no) 2002-02-18
HUP0201489A3 (en) 2004-05-28
IS6209A (is) 2001-12-21
IL146818A (en) 2007-10-31
NO20016346D0 (no) 2001-12-21
ZA200109803B (en) 2003-02-28
HK1044480A1 (en) 2002-10-25
PT1191926E (pt) 2005-07-29
BR0011894A (pt) 2002-04-02
DE60019116T2 (de) 2006-02-09
RU2240110C2 (ru) 2004-11-20
WO2000078293A1 (en) 2000-12-28
TR200103693T2 (tr) 2002-05-21
DE60019116D1 (de) 2005-05-04
JP2003502359A (ja) 2003-01-21
IL146818A0 (en) 2002-07-25
CZ20014579A3 (cs) 2002-05-15
DK1191926T3 (da) 2005-06-13
EP1191926A1 (en) 2002-04-03
UA73302C2 (en) 2005-07-15
CN1356893A (zh) 2002-07-03
HUP0201489A2 (hu) 2002-11-28
ES2235912T3 (es) 2005-07-16
CA2376226C (en) 2009-10-20
KR20020012002A (ko) 2002-02-09
AU778158B2 (en) 2004-11-18
HK1044480B (zh) 2005-08-26
SK18252001A3 (sk) 2002-09-10
AU6034400A (en) 2001-01-09
EP1191926B1 (en) 2005-03-30
CN1243547C (zh) 2006-03-01
PL352873A1 (en) 2003-09-08
CA2376226A1 (en) 2000-12-28
MXPA01012636A (es) 2002-06-21

Similar Documents

Publication Publication Date Title
SE9902386D0 (sv) New formulation
NO20012222D0 (no) Farmasöytisk formulering innbefattende omeprazol
IS2856B (is) Lyfjablanda úr ómeprasól
EE05383B1 (et) Polarlkarboksamiidhendid,ÁnendeÁvalmistamineÁjaÁkasutamineÁlipiiditasetÁalandavateÁtoimeainetenaÁningÁneidÁsisaldavÁfarmatseutilineÁkompositsioon
EE200000329A (et) Oraalne manustamisvorm happes ebapüsivate toimeainete tarbeks, selle valmistamismeetod ja happes ebapüsivat toimeainet sisaldava toimeaineühiku kasutamine
MY129356A (en) Electrospun pharmaceutical compositions
DK1169024T3 (da) Prægelatineret stivelse i en formulering med kontrolleret frigivelse
ATE431738T1 (de) Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
AP2001002237A0 (en) Hydrogel-driven drug dosage form.
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
LV10268A (lv) Terapeitiski aktivs benzimidazols un ta iegusanas panemiens
ATE254851T1 (de) Iod-herstellungszusammensetzung
SE9902387D0 (sv) New pharmaceutically active compounds
SE9604752D0 (sv) Formulation and use
GB0006897D0 (en) Medicaments
FI991115A0 (sv) Förfarande för biokybernetisk manipulering av smakligheten hos ett närngsämne eller annat ämne med fysiologisk verkan som tillförs organismen oralt ävensom produkt med anknytning till användning av förfarandet